Education
About Us
Working with TipRanks
Follow Us
Precigen (PGEN)
NASDAQ:PGEN
PGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $4.59
Previous CloseN/A
Volume729.99K
Average Volume (3M)11.84M
Market Cap
$1.27B
Enterprise Value$397.22M
Total Cash (Recent Filing)$59.75M
Total Debt (Recent Filing)$5.15M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 12, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding297,972,930
10 Day Avg. Volume29,428,039
30 Day Avg. Volume11,841,881
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue91.53
Enterprise Value/Gross Profit-1.14K
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$8.25Price Target Upside81.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Market StrategyThe commercial team is expected to target 93 Integrated Delivery Networks and community hospitals, reaching nearly 80% of the prescribing physician base, indicating a strong market strategy.
Product EfficacyFavorable durability data with a complete response seen in 43% of patients at 2 years strengthens the drug's value proposition.
Regulatory ApprovalThe FDA's unprecedented way of providing full approval without a need for a randomized study underscores the unmet need in RPR, and that the strong data package from the open-label study aided in the drug’s speedy regulatory approval.
Bears Say
Commercial AdoptionCommercial adoption if approved will take time, with only one site at the NIH experienced in administering the treatment, and critical factors like cold chain storage and cost-related barriers to consider.
Pricing ConcernsPhysicians express concerns about payor access if the treatment is priced in the $250K-$400K range, which could be a potential obstacle.
Regulatory RiskThere is regulatory risk with the current form of clinical data being single-arm and single investigator, and the ongoing confirmatory trial also being a single-arm study.
Precigen News
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $0.65 and its highest was $4.59 in the past 12 months.
What is Precigen’s market cap?
Precigen’s market cap is $1.27B.
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.
How were Precigen’s earnings last quarter?
Precigen released its earnings results on Aug 12, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.003.
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen does not currently pay dividends.
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is -0.09.
How many shares outstanding does Precigen have?
Precigen has 297,972,930 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Precigen reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Precigen?
Currently, no hedge funds are holding shares in PGEN
Precigen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (81.32% Upside)
$8.25 (81.32% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 48.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 41.7%
Last 30 Days ▲ 41.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
299.13%
12-Months-Change
Fundamentals
Return on Equity
-668.03%
Trailing 12-Months
Asset Growth
39.28%
Trailing 12-Months
Company Description
Precigen
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
PGEN Stock 12 Month Forecast
Average Price Target
$8.25
▲(81.32% Upside)
Technical Analysis
Mind Medicine
―
Meiragtx Holdings
―
Relay Therapeutics
―
Sana Biotechnology
―
Tyra Bioscience
―
Ownership Overview
64.00% Insiders
12.68% Mutual Funds
12.36% Other Institutional Investors
5.43% Public Companies and
Individual Investors